Primary Diagnoses Associated With and Outcomes of Total Knee Arthroplasty in Patients Aged 15 to 45 Years

15至45岁患者全膝关节置换术的相关主要诊断及预后

阅读:2

Abstract

BACKGROUND: Total knee arthroplasty (TKA) in younger patients is relatively uncommon. METHODS: The PearlDiver M165Ortho data set was used to identify TKA patients aged 15 to 45 years. Primary diagnoses associated with surgery were categorized into the following groups: primary osteoarthritis (OA), posttraumatic arthritis (PTOA), rheumatoid arthritis (RA), and osteonecrosis. Ninety-day adverse events and readmissions and 10-year periprosthetic fractures, loosening, stiffness, revisions, and prosthetic joint infection (PJI) were determined. Independent predictors of adverse outcomes were identified by using multivariable analysis, and Kaplan-Meier survival analysis for 10-year revisions was performed. RESULTS: A total of 26,566 TKA patients aged 15 to 45 years were identified. Among this cohort, the diagnosis associated with surgery was OA for 22,900 (86.2%), PTOA for 1648 (6.2%), RA for 1438 (5.4%), and osteonecrosis for 580 (2.2%). For the entire study cohort, 90-day adverse events were noted for 11.1% and readmissions for 7.4%. The 10-year periprosthetic fracture rate was 0.2%, aseptic loosening rate was 3.6%, stiffness rate was 26.9%, revision rate was 7.9%, and PJI rate was 5.7%. Diagnosis associated with surgery was not predictive of 90-day outcomes or 10-year adverse periprosthetic fracture, aseptic loosening, stiffness, or revisions. On Kaplan-Meier analysis, survival was clinically similar across all diagnosis groups, ranging from 86.2% to 89.7% at 10 years. CONCLUSION: Young TKA patients experience relatively low 90-day adverse events and readmissions and long-term complications regardless of diagnosis associated with surgery. Implant survival is similarly to what is observed in older TKA.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。